The secondary claim inside the Motley Fool’s “King Kong for Weight Loss” pitch is that GLP-1 medicines are about to shift from injections to pills, and that “this single shift is about to redraw the entire playing field.” That claim is real, and it deserves more attention than the marquee drug gets in some ways, because it is the part of the thesis that affects the whole category rather than one molecule. Here is the state of the oral GLP-1 race and what it means for investors.

Why Oral Delivery Changes Everything

The current generation of GLP-1 blockbusters is injected, once a week, with a needle. That single fact is a hard barrier for a large share of potential patients. Some people have a genuine needle aversion, others find the logistics of weekly injections and refrigeration burdensome, and adherence to injected medicines tends to decay over time in the real world.

A once-daily pill removes most of that friction. It fits into a morning routine the way a vitamin does, and it opens the market to patients who would simply never inject. That is why the industry treats oral delivery not as a convenience feature but as a step-change in the addressable market. The trend is real; what is less certain is who wins it.

Who Is Racing

The oral field is crowded, and that is the most important thing to understand about it. Novo Nordisk already has an oral version of semaglutide, the molecule behind Ozempic and Wegovy. Eli Lilly has its own oral candidate, orforglipron, in development. Viking Therapeutics is working on VK2735 as both an oral and an injectable, which makes it one of the more direct bets on the pill shift. And smaller names, including Veru, are pursuing early-stage oral programs of their own.

That list should temper any “single winner” framing. The oral GLP-1 market is not going to be a one-company monopoly. It will be a competitive field, likely split among the companies that already have the manufacturing scale and distribution reach to sell pills at massive volume, which is a category where the incumbent giants hold a structural advantage.

The Technical Challenge

Making a GLP-1 work as a pill is harder than it sounds, and that difficulty is part of why the race is not over. Peptide drugs like semaglutide are fragile molecules that the stomach tends to destroy before they can be absorbed. The companies pursuing oral versions have had to solve that with specialized formulation technology that protects the drug long enough to enter the bloodstream.

The tradeoff is often dose efficiency. Oral versions can require more of the active ingredient than injectable versions because so much is lost in the digestive process, which raises cost and can complicate manufacturing. The companies that solve this cleanly, with oral efficacy approaching injectable efficacy at a reasonable cost, will have a genuine edge. The ones that settle for meaningfully weaker results may find the pill is convenient but not convincing.

What It Means for the Basket

The oral angle is the quiet thesis running underneath the Fool’s six picks. Viking Therapeutics is the purest oral bet. Eli Lilly is hedged, with both retatrutide and orforglipron. The others are less direct, but all of them are framed as beneficiaries of a market that expands once pills arrive.

The honest read is that the pill shift is real but non-exclusive. It expands the pie, it does not crown a single winner, and it will take years to fully play out through trials and approvals. Our King Kong weight loss teardown explains how the “redraw the playing field” line functions in the pitch, and our Viking Therapeutics stock explainer looks at the purest oral bet in the basket.

The Bottom Line

Oral GLP-1 medicines are a genuine step change for a market that is already enormous, and the shift from shots to pills will widen access in a way that matters commercially. But it is a competitive, technically difficult race, and the biggest beneficiaries are likely to be the companies that already have scale, not a single small challenger that gets in early. Treat the pill shift as a multi-year tailwind for the category, not as a secret stock pick.

The Dosing Tradeoff

There is a quiet tradeoff behind the oral GLP-1 story that rarely makes the headlines. A pill is more convenient, but peptides are fragile molecules that the digestive system tends to destroy, so oral versions often require more active ingredient per dose than injectables. That raises cost and complicates manufacturing, and it can mean oral efficacy lands a bit below what the same molecule achieves by injection. The question for investors is whether convenience wins even if the numbers are slightly softer. For a large slice of patients, the answer is clearly yes: a daily pill at somewhat lower efficacy beats a weekly shot at higher efficacy. But the tradeoff is real, and it is one more reason the oral race will be decided by execution and cost, not just by who files first.

Ready to see the research? Click here to access The Motley Fool’s report.

NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.